Elagolix

Myovant's uterine fibroid drug looks competitive in PhIII — but can they vanquish mighty AbbVie?
Myovant's uterine fibroid drug looks competitive in PhIII — but can they vanquish mighty AbbVie?
Endpoints
Myovant
uterine fibroids
Relugolix
AbbVie
Elagolix
Flag link:
Myovant hits goal in uterine fibroid phase 3, teeing up AbbVie showdown
Myovant hits goal in uterine fibroid phase 3, teeing up AbbVie showdown
Fierce Biotech
Myovant Sciences
Relugolix
clinical trials
uterine fibroids
AbbVie
Elagolix
Flag link:
AbbVie extension study tees up elagolix for uterine fibroids
AbbVie extension study tees up elagolix for uterine fibroids
Biopharma Dive
AbbVie
uterine fibroids
Elagolix
clinical trials
Flag link:
3 Biotech Stocks With Major Potential Catalysts in July
3 Biotech Stocks With Major Potential Catalysts in July
Yahoo/Motley Fool
Neurocrine Biosciences
AbbVie
Progenics
INSYS Therapeutics
Elagolix
endometriosis
Azedra
adrenal tumors
Syndros
Flag link:
AbbVie's elagolix could put pressure on budgets, ICER estimates
AbbVie's elagolix could put pressure on budgets, ICER estimates
Biopharma Dive
AbbVie
endometriosis
ICER
Elagolix
Flag link:
Elagolix review extended
Flag link:
FDA Requires More Time to Review Abbvie and Neurocrine Endometriosis Drug Elagolix
FDA Requires More Time to Review Abbvie and Neurocrine Endometriosis Drug Elagolix
CP Wire
AbbVie
Neurocrine
FDA
Elagolix
endometriosis
Flag link:
3 Biotechs That Could Get Big Boosts in April
3 Biotechs That Could Get Big Boosts in April
Motley Fool
biotech
GW Pharma
Epidiolex
Incyte
olumiant
baricitinib
Neurocrine Biosciences
Elagolix
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Is This AbbVie's Next Blockbuster Drug?
Is This AbbVie's Next Blockbuster Drug?
Motley Fool
AbbVie
Elagolix
uterine fibroids
Flag link:
AbbVie rolls up another big win for elagolix as the prospective blockbuster sweeps endpoints in latest PhIII
AbbVie rolls up another big win for elagolix as the prospective blockbuster sweeps endpoints in latest PhIII
Endpoints
AbbVie
Elagolix
endometriosis
uterine fibroids
Flag link:
Watch These Biotechs and the FDA Calendar
Watch These Biotechs and the FDA Calendar
TheStreet.com
FDA
biotech
Dynavax
HEPLISAV-B
Progenics
Azedra
Neurocrine
Elagolix
AbbVie
Flag link:
3 Big Biotech Stocks With Major Catalysts on the Way
3 Big Biotech Stocks With Major Catalysts on the Way
Motley Fool
biotech
AbbVie
Neurocrine Biosciences
Elagolix
Celgene
ozanimod
Gilead Sciences
bictegravir
Flag link:
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
Flag link:
Neurocrine Poised To Corner Tardive Dyskinesia Market With Ingrezza
Neurocrine Poised To Corner Tardive Dyskinesia Market With Ingrezza
Seeking Alpha
Neurocrine Biosciences
Ingrezza
tardive dyskinesia
Elagolix
uterine fibroids
Flag link:
AbbVie preps an FDA pitch of promising PhIII data for blockbuster hopeful elagolix
AbbVie preps an FDA pitch of promising PhIII data for blockbuster hopeful elagolix
Endpoints
AbbVie
Elagolix
clinical trials
endometriosis
Flag link:
3 Biggest Risks for AbbVie in 2017
3 Biggest Risks for AbbVie in 2017
Motley Fool
AbbVie
Humira
biosimilars
Imbruvica
Viekira Pak
Elagolix
risankizumab
Flag link:
Elagolix May Become a Leading Uterine Fibroids Drug
Elagolix May Become a Leading Uterine Fibroids Drug
Market Realist
uterine fibroids
Elagolix
AbbVie
Neurocrine Biosciences
Flag link:
Neurocrine Biosciences Starts A Data-Rich Year On The Right Foot
Neurocrine Biosciences Starts A Data-Rich Year On The Right Foot
Seeking Alpha
Neurocrine Biosciences
AbbVie
Elagolix
Flag link:
AbbVie female health drug's success hinges on safety
AbbVie female health drug's success hinges on safety
Medical Marketing and Media
AbbVie
endometriosis
Elagolix
Flag link:

Pages